Pharmaguy's Insights Into Drug Industry News
184.9K views | +41 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy
Scoop.it!

"The Night Of" Creator is Sanofi/Regeneron Spokesperson for Atopic Dermatitis Awareness Campaign

"The Night Of" Creator is Sanofi/Regeneron Spokesperson for Atopic Dermatitis Awareness Campaign | Pharmaguy's Insights Into Drug Industry News | Scoop.it

TV writer Peter Moffat has an intimate knowledge of severe atopic dermatitis; he’s lived with it for 50 years. Moffat even wrote the condition into his hit BBC series “Criminal Justice,” which became the hit HBO miniseries “The Night Of.” Both shows feature a lawyer named Stone with noticeable atopic dermatitis on his always-sandaled feet.

 

Now, Moffat has teamed up with Regeneron, Sanofi and the National Eczema Association on an atopic dermatitis disease awareness effort called “Understand AD: A Day in the Life.” The featured “day in the life” short film is one that Moffat wrote, directed and narrated to bring the reality of eczema and atopic dermatitis into clearer view. It follows a young woman with atopic dermatitis and shows how everyday items like a sink, bleach, lotion and even a hairbrush play into her life in ways they don’t for people without the skin condition.

 

“What was great about ‘The Night Of,’ among many things, was the response of the community at large to the story of (John Turturro’s character John Stone’s) disease, which probably for the first time in American television was laid out in all its proper, full story.

 

Sanofi and Regeneron market the treatment Dupixent, approved in March as the first drug to inhibit the IL-4 and IL-13 immune system pathways, and the first new treatment in years for atopic dermatitis.

Pharma Guy's insight:

Analysts expect the drug to reach peak sales of $4 billion. Whaaa! How much does this drug cost per treatment?

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Novum Pharma – Another Valeant & Mylan: Buy Cheap, Raise Prices, Blame Middlemen

Novum Pharma – Another Valeant & Mylan: Buy Cheap, Raise Prices, Blame Middlemen | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Even in an age when prescription drugs are increasingly expensive, a $9,500 tube of gel to combat scaly skin can gain notice — especially when the price spikes 128 percent overnight.

 

That’s what happened earlier this month when a little-known company called Novum Pharma suddenly hiked wholesale prices for all three of its dermatology products by whopping amounts.

 

Novum appears to be a furtive vehicle for scooping up older medicines from other companies and then boosting prices significantly. And its chief executive did the very same thing at a previous job, at Horizon Pharma.

 

Let’s start at the beginning: Novum bought three gels to treat skin conditions in March of 2015. Two months after it acquired them, it jacked up the prices tenfold. That’s right, tenfold. For instance, the wholesale price for Alcortin A, a gel used to treat dermatitis and eczema, went from $226 to $2,995.

 

There was another big price hike earlier this year. And this month, Novum boosted prices again. Alcortin A and Aloquin each now list for $9,561 per tube. And the wholesale price for its Novacort gel rose to $7,142 from $4,186 for a small tube, according to Truven Health Analytics.

 

A Novum spokesman sent us a statement insisting the prices were inaccurate and saying they include “thousands of dollars in extra charges” added by third-party middlemen and passed on to patients. “This practice reflects one of the many fundamental challenges inherent in the healthcare system today that add to the cost of access for patients,” the statement said.

 

This is the same explanation Mylan Pharmaceuticals Chief Executive Heather Bresch gave for EpiPen price hikes.

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Dermatologists Accepted $34 Million from Pharma Companies

Dermatologists Accepted $34 Million from Pharma Companies | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Dermatologists received more than $34 million from industry in 2014, and most of that money came from pharmaceutical companies, according to a new study published in JAMA Dermatology.

Researchers in the study mined the Centers for Medicare and Medicaid Services Sunshine Act Open Payment database, which lists payments that dermatologists receive from companies making products that are reimbursed by a government-run health program. In 2014, the database’s first full year of financial data, 8,333 dermatologists received more than 208,000 payments. The top 10% of dermatologists received 90% of the total payments.

“At the center of all this is [the patient’s] concern about dishonesty and selfishness,” says says Dr. Hao Feng, the study’s first author and a dermatology resident at NYU Langone Medical Center.

Most of the payments were for food and beverage, but that’s not where the big money was spent. Speaker fees, consulting fees and payments for research represented 70% of the total money spent. The top 15 companies were all pharmaceutical manufacturers. Studies on other branches of medicine reveal that receiving industry payments and meals was linked to increased prescribing of brand-name medications, the authors write.

Pharma Guy's insight:

Hmmm... Allergan sure paid for a lot of "research" compared to Abbie, which paid for "speaking" junkets! Surprising. I wonder how different pharma companies categorize their payments to physicians. Who confirms that this process is the same at each company?

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Street Prices of Rx Brand-Name Dermatology Drugs Increase as Much as 400%!

Street Prices of Rx Brand-Name Dermatology Drugs Increase as Much as 400%! | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Drug companies always claim that the wholesale price of drugs is not an good indicator of what patients, insurers, and the government pay. So a new studypublished in JAMA Dermatology looked at the retail prices 19 brand-name prescription dermatologic drugs sold at four national chain pharmacies in the West Palm Beach, Fla., area (Costco, CVS, Sam’s Club and Walgreens) in 2009, 2011, 2014 and 2015.

The authors found that between 2009 and 2015:

  • Prices of all surveyed classes of brand-name drugs increased; the average increase was 401 percent. Prices of topical antineoplastic drugs had the greatest average absolute and percentage increase of nearly $10,927 and 1,240 percent. 
  • Prices of drugs in the antiinfective class had the smallest average absolute increase of almost $334. 
  • Prices of psoriasis medications had the smallest average percentage increase of 180 percent. 
  • The retail prices of seven drugs more than quadrupled during the study period, with the vast majority of price increases occurring after 2011. 


“Percent increases for multiple, frequently prescribed medications greatly outpaced inflation, national health expenditure growth, and increases in reimbursement for physician services,” the study concludes.

There was one surprising finding. Find out here: http://bit.ly/1MCPnLr 

more...
No comment yet.